LY2157299
Phase 2Small molecule
Eli LillyLY2157299 is one of 58 small molecule programs targeting Prostate Cancer. It is currently in Phase 2.
2
Indications
10
Total Trials
2
Active Trials
57
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
314 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 3
Androgen Deprivation Therapy
Johnson & JohnsonPhase 3
Nizoral
WWim Janssens
Phase 3
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
LHRH Agonist
RochePhase 3
Acetylsalicylic Acid
BayerPhase 3
GM-CSF
YY-mAbs Therapeutics
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Preclinical
LY2157299
Eli LillyPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Malignant Glioma2 trials
Hepatocellular Carcinoma2 trials
Prostate Cancer1 trial
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02452008·60 enrolled
Hepatocellular Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LY2157299. EMBL-EBI & Wellcome Sanger Institute.
- [4]